Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Monika Žurková (Olomouc, Czech Republic), Monika Zurková, Vítezslav Kolek, Vladimíra Loštáková, Eva Kriegová, Martina Šterclová, Vladimír Bartoš, Martina Doubková, Ilona Binková, Michal Svoboda, Jana Strenková, Martina Placková, Ladislav Lacina, Vladimir Rihak, František Petrík, Pavlína Lisá, Radka Bittenglová, Richard Tyl, Gustav Ondrejka, Hana Suldova, Jaroslav Lnenicka, Jana Pšikalová, Tomáš Snízek, Jirí Homolka, Renata Králova, Jan Kervitzer, Martina Vašáková. The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry. Eur Respir J 2016; 48: Suppl. 60, 2087

Member's Comments

No comment yet.

Related content which might interest you: Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2014 – ILDs 1 Year: 2014 Novel lung function tests in patients with interstitial lung disease (ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF clinical Year: 2016 Effect of pirfenidone on IPF progression Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases Year: 2012 Overall survival is significantly higher in sarcoidosis than in IPF patients after lung transplantation Source: Annual Congress 2013 –Clinical studies in lung transplantation Year: 2013 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 T-cell pathways in lung tissue of patients with advanced COPD and IPF requiring lung transplantation Source: International Congress 2016 – Mechanisms of disease Year: 2016 Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2008; 32: 170-174 Year: 2008 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Clinical data, lung function and cardiopulmonary exercise testing in CPFE (combined pulmonary fibrosis with emphysema). Results of a cohort of 20 patients Source: International Congress 2014 – ILDs 6 Year: 2014 Interstitial fibrosis with a nodule Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session Year: 2007 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018